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Celiac disease (CD) is an autoimmune disease prevalent in ~1% of the general 
population1. CD is unique because both the major genetic (Human Leukocyte 
Antigen-DQ2/DQ8 alleles) and etiologic factors (dietary glutens) for susceptibility 
are known2,3. While these alleles are responsible for the inappropriate T cell 
response that characterizes CD, they are not sufficient since most HLA-
DQ2+/DQ8+ individuals exposed to glutens never develop disease. The reasons for 
this have not been explained; however our novel findings strongly advocate a role 
for interleukin-23 (IL-23) in the immunopathogenesis of CD. We demonstrate that 
wheat gliadin stimulates monocytes to produce significantly higher amounts of 
inflammatory cytokines IL-1β, IL-23, and tumor necrosis factor-α (TNFα) in CD 
patients compared to HLA-DQ2+ healthy individuals. Furthermore, we determine 
that IL-1 signalling is obligatory for production of IL-23, since IL-1β triggers IL-
23 secretion in a dose-dependent manner and IL-1 receptor antagonist (IL-1ra) 
blocks IL-23 responses to gliadin. Our results suggest that gliadin activation of 
monocytes and the subsequent robust secretion of IL-1β and IL-23 initiate the 
immune response cascade that is manifest as CD, and reveal for the first time that 
the IL-1 system regulates production of IL-23. The discovery of IL-23 has 
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highlighted the critical role of the innate immune response in autoimmunity and 
other inflammatory conditions4. We anticipate that our novel findings will lead to 
the discovery of therapeutic targets for this disease and other inflammatory 
diseases mediated by IL-23.  
Celiac disease (CD) is a chronic inflammatory disorder of the small intestine 
triggered by dietary glutens in genetically susceptible individuals1. More than a decade 
of research has defined the T cell response to gluten-derived gliadin peptides in CD, yet 
the early events that initiate its activation are not well understood3,5,6. Clearly, the 
compromised intestinal epithelial barrier that characterizes CD allows gliadin access to 
the intestinal submucosa, where it must be acquired and processed by antigen presenting 
cells (APC) for presentation and activation of gliadin-specific CD4+ T cells. While 
augmented levels of zonulin and potent inflammatory cytokines IL-1β and TNFα have 
all been reported to increase intestinal permeability by disrupting the integrity of tight 
junctions in individuals with CD and other forms of inflammatory bowel disease (IBD), 
the precise mechanisms involved remain to be determined 7-9.  
A dynamic relationship between intestinal epithelial cells (IEC) and dendritic cells 
(iDC) regulates the processes of immunologic tolerance to harmless food and 
commensal antigens and adaptive immunity to pathogens10. The aberrant response to 
dietary glutens in CD immediately calls into question the maturation and activation state 
of iDC in these individuals. Indeed, a subset of activated lamina propria DQ2+ DC 
derived from circulating blood monocytes was recently implicated in the pathogenesis 
of CD 11. Moreover, circulating monocytes from CD patients have been demonstrated to 
produce substantially more TNFα and IL-8 in response to gliadin than monocytes from 
healthy individuals 12. Together, these findings suggest that CD ultimately results from 
accumulation of normally quiescent circulating monocytes that are activated upon 
encounter with gliadin in the gut.   
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Monocytes and their progeny are integral components of the innate immune 
system.  In response to environmental antigens, conserved pattern recognition receptors 
(PRR) trigger cytokine production directing the immune response to the encountered 
antigen 13. New evidence shows that activated monocytes producing IL-1β and IL-23 
are the most potent stimulators of the memory subset of pathogenic T helper cells 
(termed Th17) that secrete tissue destructive cytokines IL-17, IL-21 and IL-22 14-16.  
IL-1 was one of the first cytokines to be described and has since proved to be an 
important mediator of multiple immunologic processes throughout the body, including 
inflammatory conditions in the gut17. The IL-1 family consists of proinflammatory 
cytokines IL-1α and IL-1β and anti-inflammatory IL-1ra, which prevents IL-1 
signalling by binding the active IL-1 receptor (IL-1RI)18. An imbalance between IL-1β 
and IL-1ra, resulting from amplified levels of IL-1β  has been associated with 
inflammation in CD19. Interestingly, elimination of dietary glutens significantly 
increases levels of IL-1ra in these individuals without substantially altering IL-1β, 
suggesting that individuals with CD inherently produce more IL-1β and IL-1ra, and that 
dietary glutens may induce inflammation by shifting the balance toward IL-1β in 
individuals with CD.     
IL-23 is a relatively new inflammatory cytokine composed of the IL-12/23p40 
subunit and the IL-23p19 protein that is preferentially secreted in specific tissues by 
APC 20,21. It perpetuates chronic inflammation by stimulating both adaptive and innate 
cells to produce additional proinflammatory mediators 4. CD has been considered a 
typical Th1 disease, however emergence of the IL23-Th17 paradigm has prompted 
reanalysis of cell-mediated tissue damage previously attributed to the IL12-Th1 axis, 
and emphasized the decisive role of the innate arm in adaptive immunity. Although 
novel studies have detected augmented levels of IL-23 in rheumatoid arthritis, psoriasis, 
Crohn’s disease, ulcerative colitis and multiple sclerosis, and other cytokines associated 
4 
with Th17-mediated inflammation (IL-1β, IL-6, IL-15 and TNFα)  have been implicated 
in the pathogenesis of CD, an association with IL-23 has not yet been reported 19,22-29. 
Given the strong genetic requirement associated with CD, we investigated 
gliadin’s capacity to activate the IL-23 pathway in HLA-DQ2+ individuals with and 
without CD. We predicted that gliadin would induce increased levels of IL-23 and 
related inflammatory cytokines in HLA-DQ2+ individuals with CD compared to healthy 
individuals. To test this hypothesis, we exposed PBMC from CD patients and HLA-
DQ2+ healthy individuals to a pepsin-trypsin digest of gliadin (PTG) and analyzed 
culture supernatants for IL-1β, IL-1ra, IL-6, IL-12p70, IL-23 and TNFα. We discovered 
that PTG stimulated production of IL-23, IL-1β, IL-6 and TNFα and reduced secretion 
of IL-1ra in all donors tested, however levels of IL-1β, IL-23, IL-6 and TNFα were 
significantly higher, and IL-1ra substantially reduced, in CD patients (Figure 1a). 
Importantly, PTG did not induce IL-12p70 in any of the donors tested (negative data not 
shown). These results confirm that gliadin stimulates robust production of IL-1β and 
TNFα in individuals with CD12,19 and demonstrate gliadin’s ability to disrupt the 
balance between IL-1β and IL-1ra by simultaneously inducing high levels of IL-1β and 
decreased levels of IL-1ra. Moreover, our novel findings strongly advocate a role for 
IL-23 mediated inflammation in the pathogenesis of CD.  
In order to demonstrate that production of these potent mediators depended on 
gliadin exposure, dose response curves were generated with PTG or β-glucan, an agent 
known to activate the IL-23 pathway. Both stimuli induced dose-dependent production 
of IL-1β and IL-23, although PTG proved to be far more effective as evidenced by 
detectable levels of IL-23 achieved with 100μg/ml versus 500μg/ml of β-glucan (Figure 
1b). These stimulatory effects of PTG were not due to endotoxin contamination, since 
the presence of LPS in this preparation of PTG was ruled out in earlier studies29.      
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Several immunodominant epitopes of α-gliadin that preferentially bind HLA-DQ2 
and DQ8 molecules as well as an innate peptide p31-43 have been implicated in the 
pathogenesis of CD30. To determine if any of these epitopes were involved in activation 
of the innate immune response, we incubated PBMC with synthetic overlapping 
peptides spanning the entire sequence of α-gliadin. None of the overlapping peptides 
tested individually or in combination stimulated secretion of IL-1β or IL-23, indicating 
that other subtypes of gliadin (γ- or ω-gliadin) or additional properties of gliadin are 
required for induction of these cytokines (negative data not shown). Since gliadin is a 
glycoprotein and β-glucan recapitulates the inflammatory cytokine response generated 
by PTG, posttranslational modifications are likely necessary for pattern recognition and 
activation of APC.  
The kinetics of cytokine responses to PTG was determined by exposing PBMC to 
PTG for 6, 24, 48 and 72h. These studies revealed that IL-1β, IL-6 and TNFα were 
secreted in as few as 6h following PTG exposure, while IL-23 could not be detected 
until 24h, suggesting that induction of IL-23 required earlier inflammatory mediators 
(data not shown). During these initial studies, we also observed a positive correlation 
between IL-1β and IL-23, which led us to hypothesize that IL-1 is essential for 
production of IL-23. To directly examine the role of IL-1β in IL-23 responses, we 
treated PBMC from CD patients with IL-1ra prior to stimulation with PTG or the 
positive control, β-glucan.  IL-1ra completely inhibited induction of IL-23 in response 
to both PTG and β-glucan, illustrating the fundamental role of IL-1 signalling in IL-23 
production (Figure 2a). IL-1ra also markedly reduced levels of IL-1β in PBMC treated 
with both antigens, suggesting that IL-1β released upon engagement of PTG or β-
glucan with their respective pattern recognition receptor (PRR) perpetuates production 
of IL-1β and facilitates induction of IL-23 (Figure 2a). Additionally, PBMC were 
treated with physiologic concentrations of exogenous IL-1β in order to ascertain its 
direct effects on cytokine production. Importantly, IL-1β alone induced IL-23 
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production at much lower levels than PTG and β-glucan, indicating that additional 
signalling pathways triggered by these antigens enhance secretion of IL-23 (Figure 2b). 
These results demonstrate for the first time that the IL-1 system regulates IL-23, and 
illustrate the powerful anti-inflammatory effects of IL-1ra on induction of IL-23.  
While IL-1β is produced by many cell types, IL-23 production is thought to be 
restricted to activated APC. Recently, TLR activated monocytes were shown to secrete 
high levels of IL-23 and to be the best inducers of Th17 cells14, thus we predicted that 
monocytes were the cellular source of PTG-induced IL-23. To investigate this 
hypothesis, we exposed purified lymphocytes, monocytes, or monocyte-derived DC 
(cultured with GM-CSF and IL-4 for 72h) to PTG overnight and analyzed the cell-free 
culture supernatants for IL-23 and related “Th17” polarizing mediators. Under these 
conditions, monocytes and not their progeny DC or lymphocytes produced IL-23, IL-
1β, IL-6, TNFα and CCL20 in response to PTG, demonstrating a direct interaction 
between PTG and its anonymous PRR(s) on this population (Figure 3).   
As with whole PBMC, IL-1ra significantly inhibited IL-23 responses to PTG and 
β-glucan in purified monocytes (Figure 4a), and addition of exogenous IL-1β to this 
subset triggered a dose-dependent IL-23 response (Figure 4b). These results illustrate 
that gliadin directly stimulates monocytes to secrete IL-23 and related inflammatory 
mediators and further support a primary role for the IL-1 system in IL-23 mediated 
inflammation.  
In summary, our studies demonstrate that enzymatically digested wheat gliadin 
stimulates monocytes to produce significantly more IL-23, IL-1β and TNFα in CD 
patients than HLA-DQ2+ healthy individuals, and reveal a fundamental role for the IL-1 
system in the IL-23 pathway. We show that IL-1β directly induces monocytes to secrete 
IL-23, while its natural inhibitor, IL-1ra, substantially inhibits both the IL-1β and IL-23 
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responses generated by monocytes exposed to gliadin. Moreover, our data indicate that 
gliadin initiates the inflammatory cascade by disrupting the balance between these two 
IL-1 members, which could be targeted therapeutically for treatment of this disease and 
other conditions associated with IL-23 mediated inflammation. 
Methods 
Cells. Peripheral blood mononuclear cells (PBMC) were isolated from Celiac patients’ 
and healthy donors’ whole blood by density gradient centrifugation in Lymphocyte 
Separation Medium (ICN Biomedicals Inc.). PBMC were viably cryopreserved in 
RPMI-1640 media (Invitrogen Corp.) containing 20% human AB serum (hAB) (Gemini 
Bioproducts) and 10% Dimethylsulfoxide (Sigma) using an automated cell freezer 
(Gordinier Electronics), and stored in the vapor phase of liquid nitrogen until used. 
Highly purified monocytes (95% purity) were obtained from healthy donors as above 
followed by countercurrent centrifugal elutriation.  The resulting cells were viably 
cryopreserved in fetal bovine serum (Summit Biotechnology) containing 10% DMSO 
and 5% glucose (Sigma) for later use. All individuals gave informed consent for 
peripheral blood drawn for this study. The study protocol was approved by the 
Institutional Review Board at the University of Maryland School of Medicine.  
DNA Extraction and HLA Typing. DNA was extracted from a portion of the PBMC 
using the QIAamp DNA Mini Kit (Qiagen) per the manufacturer’s instructions. DNA 
was analyzed by spectrophotometry to determine quantity and purity and stored at –
20°C until used. Alleles of genes encoding HLA were identified using One Lambda 
Micro SSP™ ABDR Typing Kit, and alleles of genes encoding HLA-DQ were 
determined by DQA1 and DQB1 SSP UniTray® Kit (Dynal Biotech) following the 
manufacturer’s.    
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Reagents. Gliadin was prepared by enzymatic digestion as described previously29. The 
presence of contaminating endotoxin in gliadin was determined by Limulus amebocyte 
assay per the manufacturers’ instructions. 100mg of β-D-glucan from barley (Sigma) 
was dissolved in 600ul 95%EtOH followed by 9mL distilled water.  The resultant slurry 
was stirred vigorously at 100°C for 3 minutes, allowed to cool, and stored at 10mg/ml at 
4°C until used. 25 overlapping 20mers spanning the sequence of α-gliadin were 
synthesized and purified >95% at the University of Maryland Biopolymer Lab, and 
stored at –20°C until used. Recombinant human IL-1β and IL-1ra were purchased from 
R & D Systems. 
PBMC cultures. PBMC from CD patients and HLA-DQ2+ healthy controls was tested 
as follows. 106PBMC/ml were incubated in RPMI-1640 supplemented with 10% heat 
inactivated hAB, 1% L-glutamine, 1% Pen-Strep and 20mM Hepes Buffer (cRPMI) 
with and without PTG, β-glucan, 5ng/ml rhIL-1β, or 10μg/ml pooled synthetic 20mers 
of α-gliadin in 96 well U-bottom plates (Denville Scientific Inc.) at 37 °C in 5% CO2 
for 6, 24, 48, or 72h. Alternatively, 106PBMC/ml were incubated with 0.5μg/ml rhIL-
1ra at 37 °C in 5% CO2 for 1h then cultured with and without 100μg/ml PTG or 
500μg/ml β-glucan for an additional 20h. Cell-free culture supernatants were harvested 
for cytokine and chemokine analysis.  
Elutriated monocyte cultures. 5 x 105monocytes/ml were cultured in cRPMI with and 
without 100μg/ml PTG, 100μg/ml β-glucan, or 0.5-50ng/ml rhIL-1β in 96 well U-
bottom plates at 37 °C in 5% CO2 for 20h. Alternatively, 5 x 105monocytes/ml were 
incubated with 0.5μg/ml rhIL-1ra at 37 °C in 5% CO2 for 1h then cultured with and 
without 100μg/ml PTG or β-glucan for an additional 20h. Cell-free culture supernatants 
were harvested for cytokine and chemokine analysis. 
Cytokine & chemokine analysis. Cell-free culture supernatants were analyzed for IL-
1β, IL-1ra, IL-6, IL-12p70, IFNγ, TNFα (Bio-Plex Cytokine Assay kit, Bio-Rad) or IL-
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1β, IL-23 (ELISA kit, eBiosciences), IL-1ra and CCL20 (Quantikine ELISA kit, R & D 
Systems) following the manufacturers’ protocols. Appropriate standard curves were 
included in each assay. 
Statistical analyses. Data are presented as mean values + s.d. P values comparing 
different conditions within the same individuals were calculated using paired two-tailed 
Student’s t tests and p values comparing the two study groups were determined by 
unpaired two-tailed Student’s t tests (Figure 1a).  P values < 0.05 were considered 
statistically significant. 
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Figure 1 Gliadin induces robust production of IL-23 and related proinflammatory 
cytokines in PBMC from CD patients. (a) PBMC from CD patients generate 
significantly higher amounts of IL-23, IL-1β and TNFα in response to PTG 
stimulation than HLA-DQ2+ healthy individuals. PTG substantially reduces 
secretion of the anti-inflammatory cytokine IL-1ra in CD patients but not in 
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healthy individuals, and only stimulates significant levels of IL-6 in CD patients. 
PBMC from 7 CD patients and 6 HLA-DQ2+ healthy individuals (HD) were 
incubated with or without PTG (100μg/ml) for 48h, and cell-free culture 
supernatants analyzed for production of IL-1β, IL-1ra, IL-6, IL-12p70, IL-23 and 
TNFα. Together, these data illustrate that proinflammatory cytokine responses 
to PTG are augmented in HLA-DQ2+ individuals with CD compared to those 
without disease. Error bars indicate + s.d. (b) PTG stimulation of IL-23 and IL-
1β production is dose dependent. PBMC from CD patients were cultured with or 
without 25, 100, 250 or 500μg/ml PTG for 24h. Increasing doses of β-glucan 
from barley served as a positive control. Concentrations of IL-23 and IL-1β were 
quantified by ELISA. Data represents mean values from 3 independent 
experiments. Error bars indicate + s.d. 
Figure 2 IL-1 cytokines regulate the IL-23 response in vitro. (a) Addition of IL-
1ra significantly inhibits IL-23 and IL-1β responses to PTG and the positive 
control, β-glucan. PBMC were incubated with or without 0.5μg/ml IL-1ra for 1h 
prior to stimulation with PTG or β-glucan for 20h. Secretion of IL-23 and IL-1β 
were determined by ELISA. These data are mean values from 10 independent 
experiments. Error bars indicate + s.d.  (b) IL-1β alone stimulates PBMC to 
produce IL-23, however its capacity to do so is much lower (~10-fold) than that 
of PTG or β-glucan. PBMC were cultured in the absence or presence of 5ng/ml 
IL-1β for 20h, and supernatants tested by IL-23 ELISA. These results represent 
the mean of 10 independent experiments. Error bars indicate + s.d. 
Figure 3 Monocytes are the cell source of IL-23 and related proinflammatory 
mediators produced in response to in vitro gliadin stimulation. Highly purified 
lymphocytes, monocytes or monocyte-derived immDC were incubated with or 
without PTG (100μg/ml) for 24h, and supernatants analyzed for production of 
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IL-1β, IL-6 IL-23, TNFα and CCL20. PTG directly activates monocytes, and not 
lymphocytes or immature DC, to secrete IL-23. IL-1β, TNFα, IL-6 and CCL20 
responses were also generated by monocytes exposed to PTG, and not their 
progeny DC.  IL-23 data represent the mean of 5 independent experiments. IL-
1β, TNFα and IL-6 data represent the means of 3 independent experiments. 
CCL20 data is one representative of 3 independent experiments. Error bars 
indicate + s.d. 
Figure 4 The IL-1 system regulates IL-23 production in human monocytes. (a) 
IL-1ra significantly inhibited IL-23 responses from monocytes exposed to PTG 
and the positive control, β-glucan. Highly purified monocytes were incubated 
with or without 0.5μg/ml IL-1ra prior to addition of PTG or β-glucan for 20h. 
These results represent the means of 5 independent experiments. Error bars 
indicate + s.d. (b) IL-1β alone directly activates monocytes to secrete IL-23 in a 
dose dependent manner, however its capacity to do so is greatly reduced (~10-
fold) compared to that of PTG or β-glucan. Purified monocytes were treated with 
and without 0.5, 5 or 50ng/ml rhIL-1β for 20h, and culture supernatants were 
analyzed for IL-23 production. These results represent the means of 5 
independent experiments. P values compare IL-1β data sets to medium alone. 
Error bars indicate + s.d. 
 




